Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
Zacks Investment Research on MSN3d
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung CancerJ&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.
Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...
How can we tell whether EGFR inhibitors effectively inhibit the key pathways driving EGFR-mediated radioresistance? Considering tumor instability and heterogeneity, how can we optimize the ...
Signal transduction pathways implicated in radiosensitization by EGFR inhibitors. Tyrosine phosphorylation on key intracellular residues of EGFR recruits docking proteins, including the SH2 domain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback